WHO proposal of a new strategy for the control of malaria, intermittent treatment using sulfadoxine-pyrimethamine, encounters various conceptual and logistic problems. First, the treatment is dedicated only to a very small part of the population which is not representative of the population at risk. Secondly, it largely underestimates the risks of this type of drugs. At last, the difficulties of its management should lead to hamper this strategy. It would be preferable to study the real causes of the current strategy failure and to take it into account for a new strategy.